STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13D/A] Regencell Bioscience Holdings Limited SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
The information had reflected the effect of the Issuer's 38-for-one forward stock split paid in the form of a stock bonus on June 13, 2025 (the "Forward Stock Split").


SCHEDULE 13D




Comment for Type of Reporting Person:
The information had reflected the effect of the Forward Stock Split.


SCHEDULE 13D


Regencell (BVI) Limited
Signature:/s/ Yat-Gai Au
Name/Title:Yat-Gai Au, Sole Director
Date:07/11/2025
Yat-Gai Au
Signature:/s/ Yat-Gai Au
Name/Title:Yat-Gai Au
Date:07/11/2025
Regencell Bioscience Holdings Ltd

NASDAQ:RGC

RGC Rankings

RGC Latest News

RGC Latest SEC Filings

RGC Stock Data

6.56B
56.59M
96.16%
0.14%
0.38%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Hong Kong
Causeway Bay